Pharmaceutical compositions useful in prevention and treatment of beta-Amyloid protein-induced disease

A method for the treatment of beta-Amyloid protein induced cytotoxicity in a human brain comprising administering to a subject suffering from the beta-Amyloid protein-induced cytotoxicity a therapeutically effective amount of a compound having the formula (I):

• or a compound having the formula (II):
• or a compound having the formula (III):
• or pharmaceutically acceptable salts or esters thereof, wherein:
• the dotted configuration- - - - is optionally a single bond or a double bond.
• R1 is selected from the group consisting of H, OH, OMe, and OR50 wherein R50 is alkyl, alkenyl, or alkynyl;
• R2 is selected from the group consisting of H, OMe, and OR50 wherein R50 is alkyl, alkenyl, or alkynyl;
• R3 is selected from the group consisting of H, OMe, and OR50 wherein R50 is alkyl, alkenyl, or alkynyl;
• R4 is selected from the group consisting of H, OH, OMe, and OR50 wherein R50 is alkyl, alkenyl, or alkynyl;
• R5 is selected from the group consisting of H, OH, OMe, OR50, and X wherein R50 is alkyl, alkenyl, or alkynyl, and X is F, Cl, Br, or I;
• R6 is selected from the group consisting of OH, OMe, OR50, and X wherein R50 is alkyl, alkenyl, or alkynyl, and X is F, Cl, Br, or I;
• R7 is selected from the group consisting of H, OMe, and OR50 wherein R50 is alkyl, alkenyl, or alkynyl;
• R8 is selected from the group consisting of OH, OMe, OR50 and X wherein R50 is alkyl, alkenyl, or alkynyl, and X is F, Cl, Br, or I;
• and
• R9 is selected from the group consisting of H, OMe and OR50 wherein R50 is alkyl, alkenyl, or alkynyl.